A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone to That of High Dose Interferon (Betaseron or Rebif) in the Treatment of Relapsing Multiple Sclerosis Patients.

Trial Profile

A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone to That of High Dose Interferon (Betaseron or Rebif) in the Treatment of Relapsing Multiple Sclerosis Patients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2010

At a glance

  • Drugs Glatiramer acetate; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 09 Nov 2008 'Teva Pharmaceutical Industries' added as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Actual patient number (91) added as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top